The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated
